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Background: In Spain, cervical cancer prevention is based on opportunistic screening, due to the disease’s
traditionally low incidence and mortality rates. Changes in sexual behaviour, tourism and migration have, however,
modified the probability of exposure to human papilloma virus among Spaniards. This study thus sought to evaluate
recent cervical cancer mortality trends in Spain.
Methods: We used annual female population figures and individual records of deaths certified as cancer of cervix,
reclassifying deaths recorded as unspecified uterine cancer to correct coding quality problems. Joinpoint
models were fitted to estimate change points in trends, as well as the annual (APC) and average annual
percentage change. Log-linear Poisson models were also used to study age-period-cohort effects on mortality
trends and their change points.
Results: 1981 marked the beginning of a decline in cervical cancer mortality (APC1981–2003: −3.2; 95% CI:-3.4;-3.0)
that ended in 2003, with rates reaching a plateau in the last decade (APC2003–2012: 0.1; 95% CI:-0.9; 1.2). This trend,
which was observable among women aged 45–46 years (APC2003–2012: 1.4; 95% CI:-0.1;2.9) and over 65 years
(APC2003–2012: −0.1; 95% CI:-1.9;1.7), was clearest in Spain’s Mediterranean and Southern regions.
Conclusions: The positive influence of opportunistic screening is not strong enough to further reduce
cervical cancer mortality rates in the country. Our results suggest that the Spanish Health Authorities should
reform current prevention programmes and surveillance strategies in order to confront the challenges posed
by cervical cancer.
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Cervical cancer is one of the most frequent female tu-
mours world-wide, ranking second in incidence and
fourth in mortality [1,2]. Rates vary widely depending
on: a) the prevalence of the human papilloma virus
(HPV) infection that causes this neoplasm [3]; and, b)
access to and effectiveness of programmes for the early
diagnosis and treatment of precancerous lesions, which* Correspondence: bperez@isciii.es
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article, unless otherwise stated.can reduce the incidence of invasive cervical cancer in
screened groups by approximately 80% [4].
In Spain, cervical cancer mortality rates used to be
among the lowest in Europe [5]. However, the social
changes experienced since the 1980’s –in the form of
more liberal sexual behaviour and increased contact with
people from regions with higher prevalence of infection
[6,7]- have increased the risk of exposure to HPV among
Spanish females in general, and among the younger co-
horts in particular. Furthermore, the Spanish National
Health Service’s fast pace of growth and decentralisation
has modified both the coverage and quality of opportunis-
tic cervical cancer screening. These factors, which may
well have affected the epidemiology of cervical cancer,
taken together with the recent incorporation of HPV vac-
cination strategies render it necessary for the pertinentCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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able to assess the future impact of preventive measures.
The study of cervical cancer mortality has always been
hampered by the widely known phenomenon of under-
registration in the certification of this cause of death [8].
In Spain, deaths coded as not otherwise specified sites of
the uterus (U-NOS) represented almost 70% of all uter-
ine cancer deaths in the early 1980s, and less than 25%
since 2000. This gradual improvement in data quality,
which has not been taken into account in the most re-
cent study on cervical cancer mortality in Spain [9], dir-
ectly affects and distorts time trends. To avoid the bias
flowing from these changes, we reclassified U-NOS in
accordance with IARC strategy [10], to analyse trends in
cervical cancer mortality in Spain across the period
1981–2012, both overall and by age group and region,
and fitted age-period-cohort models by incorporating a
novel approach that enables possible change-points in
cohort or period effects to be estimated.Methods
Data on mid-year population and individual death re-
cords for the period 1981–2012 were obtained from the
National Statistics Institute [11]. We selected all female
deaths registered as cervical cancer (ICD-9:180; ICD-10:C53),
cancer of the corpus uteri (ICD-9:182.0; ICD-10:C54) and
U-NOS (ICD-9:-179; ICD-10:C55), broken down by 5-year
age-groups (0–4,…, 80–84 and ≥85 years).Reallocation of U-NOS
U-NOS deaths were reallocated to either cervical or cor-
pus uteri cancer in line with the strategy adopted by
Loos et al. [10]. They defined 5 age groups (0–39, 40–49,
50–59, 60–69 and ≥70 years), and quantified the annual
age-specific proportion of cases registered as cervical can-
cer among all uterine cancer deaths, excluding U-NOS;
these proportions were then applied to U-NOS to esti-
mate cervical cancer deaths. In any case where U-NOS
represented more than 25% of all uterine cancer deaths,
these authors recommended the use of an external “refer-
ence population” having high data quality. In line with this
criterion, Loos et al. applied age-specific proportions from
Dutch mortality data to correct Spanish figures until 1999.
Although we followed this suggestion for the period
1981–1999, we used Spanish data to compute age-specific
proportions for the period 2000–2012 because U-NOS
represented less than 25% of all uterine cancer deaths
from 2000 onwards. As the selection of the external popu-
lation is arbitrary, we evaluated the variability in our esti-
mates by means of different approaches, namely, by
applying: a) Dutch data-based proportions for the whole
period; and b) Spanish proportions for the entire period
(Additional file 1: Table S1).Age-standardised rates and Joinpoint regression analysis
We calculated crude and age-standardised mortality
rates (European standard population) for each five-year
period (from 1981–1986 to 2006–2010) by Autonomous
Region (Comunidad Autónoma) (Andalusia; Aragon;
Asturias; Balearic Islands; Canary Islands; Cantabria;
Castile-La Mancha; Castile & Leon; Catalonia; Valencian
Region; Extremadura; Galicia; Madrid; Murcia; Navarre;
Basque Country; La Rioja; Ceuta and Melilla), and also
computed truncated age-standardised rates for the follow-
ing age groups, namely, 0–19, 20–44, 45–64 and > =65 years.
Additionally, annual age-standardised mortality rates and
their corresponding standard errors were calculated to
study time trends. We used the NCI-Joinpoint regression
analysis programme [12] to evaluate the presence of
change points and estimate the annual percentage change
(APC) and average annual percentage changes (AAPC),
which are regarded as useful summary measurements
even in cases where models may indicate the presence of
changes in trend during the study period [12].
Age–period–cohort models
Log-linear Poisson models were fitted to study the effect
of age, period of death and birth cohort on mortality
trends. For this purpose, five-year age-groups and quin-
quennia for the period 1981–2010 were used, excluding
the open-ended category of persons aged over 85 years
and women aged <20 years, due to the limited number of
deaths. To overcome the problem of non-identifiability of
model parameters arising from exact linear dependence
among age, period, and cohort [13], we adopted the ap-
proach proposed by Holford [14], and considered estim-
able functions of parameters, such as the curvatures in
each effect and the sum of period and cohort linear slopes,
also known as net drift. We estimated effects curvature
and net-drift, which are uniquely determined by the data
and hence remain invariant irrespective of the particular
approach used [15], and displayed the cohort and period
effects graphically. We also checked for extra-Poisson dis-
persion [16].
Curvature change points
To detect changes in the period and cohort effects of the
three-factor model, separate Joinpoint regression analyses
of the estimated period and cohort curvatures were per-
formed with weights inversely proportional to their esti-
mated variances [17]. These models provided the number
of significant change-points across periods and cohorts by
using permutation tests, their estimated locations and the
associated changes in slopes.
Results
From 1981 to 2012, a total of 16,669 deaths were ori-
ginally certified as cervical cancer deaths in Spain.
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ber of estimated deaths due to this tumour rose to
26,699. The original and corrected figures for cervicalTable 1 Cervical cancer deaths (original and corrected): Spain
Cervical cancer deaths (C53) All uterine canc
Original Corrected
N N










<45 years 2541 3339
45 to 64 years 6471 10081 1






Basque Country 710 1160
Navarre 131 248
Central Region
Castile & Leon 852 1497




La Rioja 77 144
Mediterranean & Southern region
Catalonia 2776 4254
Valencian Region 1765 2897
Murcia 438 718
Andalusia 2963 4892 1
Balearic & Canary Islands
Balearic Islands 546 769
Canary Islands 976 1260
Autonomous City enclaves (North Africa)
Ceuta 40 61
Melilla 40 58
aNOS: not otherwise specified.cancer deaths, as well as the distribution of U-NOS
by period, age group and region can be evaluated in
Table 1.,1981-2012
er deaths (C53-C55) U-NOSa deaths (C55)




9899 22762 38% 44%
9400 6392 68% 50%
9082 4813 53% 47%
9038 3525 39% 45%
8928 2500 28% 41%
9000 2160 24% 36%
9992 2198 22% 37%
4459 936 21% 35%
3704 926 25% 88%
7279 6220 36% 57%
8916 15566 40% 37%
4982 2142 43% 45%
2173 717 33% 44%
860 267 31% 44%
2852 1027 36% 44%
719 288 40% 41%
3647 1459 40% 44%
2560 1075 42% 44%
1462 702 48% 44%
6011 1863 31% 45%
1975 869 44% 43%
395 150 38% 45%
9612 3364 35% 44%
6532 2547 39% 44%
1624 617 38% 45%
0402 4265 41% 45%
1465 498 34% 45%
2432 632 26% 45%
101 45 45% 47%
95 32 34% 55%
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rates for the whole period, overall and by age-group, with
a detailed breakdown being shown in Table 2.
Cervical cancer mortality experienced a marked de-
crease (AAPC: −2.2%; 95% CI −2.6; -1.9) but underwent
two different phases: a) an initial period (1981–2003), with
rates decreasing by −3.2% per annum (95% CI: −3.4; -3.0);
and b) a second period, from 2003 to the end of the study
period, with stable rates (APC: 0.1%; 95% CI: −0.9; 1.2). A
breakdown by age group showed that both middle-aged
(45–64 years) and older women (≥65 years) registered
similar trends, with mortality clearly declining until 2003
(APC45–64:-3.3; 95% CI:-3.7;-3.0; APC≥65:-4.0; 95% CI:-
4.4;-3.5) and rates levelling-off thereafter. In the younger
groups (20–44 years), in contrast, cervical cancer mortality
was initially stable but from 1995 onwards rates began to
decrease by around −2.6% per annum (95% CI: −3.6; −1.7).
Time trends by geographical area also reflect this same
pattern, i.e., cervical cancer mortality decreased in all re-
gions, with average annual percentage changes ranging
from −1.7 (Castile-La Mancha) to −3.4 (Catalonia). How-
ever, recent trends in the Mediterranean and Southern re-
gion merit special attention: whereas their high mortality
rates initially experienced a steep fall of around −4% per
annum, in recent years these trends have changed, with
mortality remaining stable in the Valencian Region (APC:
0.8; 95% CI:-1.6; 3.2) and Andalusia (APC: 0.3; 95% CI:-2.2;
2.9), and displaying a fairly unsteady trend in Catalonia
(APC2004–2010: 3.6; 95% CI:-2.2; 9.6; APC2010–2012: −12.3;
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Figure 1 Cervical cancer mortality in Spain (1981–2012). Observed age-stan
by age group. Points: observed age-standardised rates. Lines (dashed a
from Joinpoint).Joinpoint regression models could not be fitted for the
Autonomous City enclaves of Ceuta and Melilla; their
mortality rates, which remain high, have almost halved in
the last two years, though these changes might be due to
the high variability in rates. The change in age-specific
proportions did substantially not modify any of these re-
sults (Additional file 1: Table S1).
Figure 2 shows the age-specific mortality rates by birth
cohort and graphically depicts the results of the age-
period-cohort analysis, drawn from the best-fit model
which included the three components (age + period +
cohort). As expected, cervical cancer mortality rates in-
creased with age, stabilised at around the age of 60 years
and then started rising again. As regards the cohort
effect, our analysis identified two significant change
points: dating from the beginning of the 20th century,
risk declined markedly with birth cohort until the early
years after the Spanish Civil War. At about this time
-the early 1940’s- the probability of dying due to cervical
cancer in Spanish women began to increase by birth-
cohort until 1962, when the risk again moved sharply
downward. The fluctuating cohort effect in the most re-
cent generations reflects the instability of rates in these
birth cohorts, solely represented in our study by women
in the youngest age-groups which have a very small
number of deaths. Insofar as the period effect was con-
cerned, our results suggest a decline in risk until 2003,
followed by stabilisation in the last five-year period,
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Deaths 1981 1986 1991 1996 2001 2006 2011 1981 1981-2012 First period Change point Second period Change point Third period
N 1985 1990 1995 2000 2005 2010 2012 2012 % (95% CI) % (95% CI) Year (95% CI) % (95% CI) Year (95% CI) % (95% CI)
Total 27 26699 4.9 4.3 3.6 3.1 2.6 2.6 2.6 3.4 −2.2 (−2.6;-1.9) −3.2 (−3.4;-3.0) 2003 (2001–05) 0.1 (−0.9;1.2)
Age group*
20-44 years 28 3328 1.6 1.6 1.7 1.6 1.3 1.2 1.1 1.4 −1.4 (−2.2;-0.6) 0.1 (−1.2;1.5) 1995 (1990–00) −2.6 (−3.6;-1.7)
45–64 years 14 10081 9.7 8.1 6.7 5.8 5.0 5.2 5.6 6.6 −2.0 (−2.4;-1.5) −3.3 (−3.7;-3.0) 2003 (2000–06) 1.4 (−0.1;2.9)
≥65 years 43 13279 17.6 15.3 12.3 9.7 8.0 8.2 7.6 11.0 −2.9 (−3.4;-2.3) −4.0 (−4.4;-3.5) 2003 (2000–05) −0.1 (−1.9;1.7)
Geographical area
Northern Region
Galicia 40 2368 5.4 5.3 4.1 4.0 3.2 2.9 3.4 4.0 −2.4 (−2.8;-1.9)
Asturias 30 921 4.9 4.8 4.7 3.7 2.3 3.0 2.5 3.8 −2.6 (−3.4;-1.7)
Cantabria 41 360 4.5 4.4 3.7 3.1 2.8 2.5 2.6 3.4 −2.4 (−3.4;-1.4)
Basque Country 19 1160 3.9 3.4 2.7 2.3 2.3 2.4 2.0 2.7 −2.2 (−2.8;-1.5)
Navarre 25 248 2.3 3.3 2.1 1.5 1.9 1.8 2.0 2.1 −1.9 (−3.2;-0.5)
Central Region
Castile & Leon 27 1497 3.9 3.4 2.6 2.7 2.3 2.1 2.5 2.8 −2.2 (−2.8;-1.6)
Castile-La Mancha 33 1035 4.6 3.3 2.8 2.4 2.1 2.6 2.4 2.9 −1.7 (−3.1;-0.3) −3.9 (−5.0;-2.7) 2002 (1991–05) 3.1 (−0.9;7.2)
Extremadura 39 583 4.4 3.0 3.0 2.2 2.2 2.1 1.9 2.7 −2.7 (−3.5;-1.8)
Madrid 21 2728 3.3 3.4 3.1 2.7 2.3 2.1 2.2 2.7 −2.0 (−2.5;-1.4)
Aragon 31 746 4.0 3.2 3.3 2.5 2.1 2.0 2.0 2.7 −2.7 (−3.5;-1.9)
La Rioja 23 144 4.5 2.1 2.8 1.8 1.8 2.5 3.1 2.6 −1.7 (−4.1;0.7)
Mediterranean & Southern Region
Catalonia 20 4254 5.3 4.6 3.7 2.9 2.2 2.5 2.2 3.3 −3.4 (−5.3;-1.6) −4.4 (−4.9;-3.9) 2004 (1984–07) 3.6 (−2.2;9.6) 2010 (2001–10) −12.3 (−32.2;13.3)
Valencian Region 21 2897 5.7 4.5 3.6 3.4 2.9 2.8 3.2 3.6 −2.1 (−3.0;-1.3) −3.5 (−4.2;-2.8) 2002 (1990–09) 0.8 (−1.6;3.2)
Murcia 33 718 5.5 4.6 4.7 3.6 2.5 2.7 2.6 3.6 −2.9 (−3.7;-2.1)
Andalusia 40 4892 6.0 4.7 4.1 3.5 3.0 2.8 2.8 3.8 −2.5 (−3.2;-1.8) −3.5 (−3.9;-3.0) 2004 (1993–08) 0.3 (−2.2;2.9)
Balearic & Canary Islands
Balearic Islands 22 769 6.6 7.6 6.3 3.9 4.2 3.6 3.4 5.0 −2.9 (−3.8;-2.0)
Canary Islands 15 1260 7.1 5.6 5.1 4.3 3.7 4.0 4.1 4.7 −2.0 (−2.6;-1.4)
Autonomous City enclaves (North Africa)
Ceuta 30 61 7.9 6.1 7.7 3.4 6.1 5.5 2.2 5.8
Melilla 58 58 5.8 7.4 6.2 9.1 4.7 5.9 2.8 6.2
*Age group 0–19 years: total number of cases for the whole period: 11 cases; rates not shown.
+Joinpoint regression trend analyses by age group and geographical region.














Figure 2 Cervical cancer mortality in Spain (1981–2010); age-period-cohort analysis. a) Deviance table for age-period-cohort models; b) Trends in
age-specific rates by birth cohort; c) Cross-sectional age effect for an average period; d) Curvature of period and cohort effects and change points
in cohort curvature (vertical grey lines).
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This study describes invasive cervical cancer mortality
trends in Spain over the last 32 years. If the whole period
is considered, mortality rates have clearly declined; never-
theless, our report’s most relevant result is the change in
trend detected in the last ten years, when rates stopped
falling and reached a plateau. This trend is more evident
in Spain’s Mediterranean and Southern regions, and can
be observed in women both in the 45- to 65- and over 65-
year age ranges. Younger women, in contrast, displayed a
different temporal pattern, with stable rates until 1995
and a significant decline, of close on 3% per annum, there-
after. While mortality is the most comprehensive and
homogeneous source of information on cancer in Spain,
there is a clear under-registration when it comes to certifi-
cation of death due to this tumour in Spain [8]. To ad-
dress this problem, we adopted a simple, reproducible and
widely used strategy [10,18,19], yet its clearest limitation
resides in the possible non-representativeness of the selec-
tion of the reference population. Our sensitivity analyses
reinforce the reliability of our results.
In most developed countries, cervical cancer mortality
rates have fallen markedly since the introduction of sys-
tematic cytological screening [20]. In Spain, Joinpoint ana-
lysis shows a decline in mortality until 2003, which is line
with the moderate decrease in incidence reported for theperiod 1980–2004 [21]. The opportunistic Spanish cervical
cancer screening programme, taken together with the ad-
vances in cervical cancer treatment, probably explains the
trend observed in this initial period. The country’s socio-
logical evolution may have strengthened the impact of the
preventive effect of this screening at a population level.
According to our age-period-cohort models, the trend in
the risk of dying due to this tumour changed among
women born between 1950 and 1960: Spanish women,
who had a low prevalence of HPV and low cervical cancer
rates, experienced a marked transformation in their social
role in the latter years of Franco’s military dictatorship and
early years of democracy, and underwent major changes in
their habits, including their sexual and smoking behaviours
[6]. Highly educated women played a pioneering role in
this process. At this time, more conservative sexual be-
haviours (i.e., life-long monogamy) were more usual
among females with a primary or lower educational level
than among those with a university education (80% vs.
50%) [6]. As such women with a higher educational level
are usually more prone to attend cytological screening [7],
the opportunistic strategy may have unintentionally
targeted this high-risk subgroup in the latter part of
the 20th century.
Recently, however, some countries, such as The
Netherlands [22], USA [23] and England [24], have
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cer, with a slow-down in the decline in rates. In Spain, this
shift in the trend has been more marked, in that mortality
has even stopped declining and levelled off, indicating that
the positive influence of opportunistic screening is cur-
rently not strong enough to offset increased exposure to
HPV. Nowadays, the combination of the generalisation of
more permissive sexual behaviours [6,25] and international
tourism have increased the probability of exposure to HPV
among all Spanish women. The mean age of first sexual
intercourse among Spanish girls in the 1970–1980 birth
cohorts is more than one year younger than that of the
1950–1960 birth cohorts [6,25], thereby favouring earlier
HPV infection and more persistent cases, due to cervical
immaturity. The proportion of non-sexually active females
has also dropped over time, and women –as well as men-
have clearly increased their lifetime number of sexual part-
ners [6,25], facilitating the acquisition of high-risk VPH.
Despite the fairly extensive population coverage of cervical
screening -around 72% of Spanish women over the age of
25 years report undergoing at least one cytology screening
test (Pap smear) in their lives [26]- there is still a wide gap
between the proportion of never-screened women among
those in higher managerial or professional positions and
those employed as unskilled workers (15% vs. 36%) [26],
and many women are still being diagnosed without ever
having attended any screening test whatsoever [27].
The divergent trend seen in the youngest age group is
extremely interesting, however. Among these women,
mortality rates were stable until 1995, at which point they
started to decline by 2.7% per annum. These differences
among age groups have also been observed in cervical can-
cer incidence [21]. Even though sexual behaviours that fa-
cilitate exposure to HPV are more prevalent among young
Spanish females [28], health surveys indicate that they are
also more likely to report a recent Pap smear [26,29].
There was also evidence of a certain degree of hetero-
geneity in time trends by geographical area, with the sta-
bilisation in mortality figures being mainly found in
south-west Spain and rates in other regions still on the
decline. Cervical cancer mortality in Spain is quite vari-
able by region, with rates traditionally being lower in the
more conservative areas in central Spain than in the
coastal regions (Additional file 2: Figure S1). Health sur-
veys show that women in the Mediterranean and Southern
region, and on the islands, where beach tourism has for
many years been one of the main economic activities, re-
port a younger age at first sexual intercourse and a higher
number of sexual partners [6]. Health policy decisions
have also to be considered when studying spatial vari-
ation, as the Spanish National Health Service is heavily
decentralised, with very important organisational differ-
ences in preventive protocols and coverage as between the
various regions [29], i.e., in some areas, such as Asturias,La Rioja and Castile & Leon, public health screening has
been reinforced and is not purely opportunistic, since
part of the population is invited to attend by the health
authorities [30], while in others, private health practices
have a very relevant share in cervical cancer screening
coverage [31]. Hence, more than 20% of women in
Madrid, Catalonia and the Balearic Islands have double
(public and voluntary private) health insurance coverage,
as compared to the low proportion found in other areas
(i.e., less than 3% in Navarre, Cantabria and Melilla) [26].
The relevance of the immigrant population in Spain
warrants special attention. Since the 1990’s, Spain has be-
come the destination for an important influx of immi-
grants from countries with higher rates of cervical cancer
[11]. The total number of foreigners residing in Spain in-
creased from 350,000 in 1991 to 1,600,000 in 2001,
and rose to 5,250,000 in 2011 [11]. Female immigrants
currently account for over 13% of women in some re-
gions (such as the Balearic and Canary Islands, Catalonia,
Valencian Region, Murcia and Madrid), and have two very
different profiles: a) young women, coming mainly from
South America (i.e., Ecuador, Colombia and Bolivia),
Eastern Europe (Romania, Bulgaria and Poland) and
North Africa (mostly Morocco), who represented 17% of
all women aged 20 to 44 years residing in Spain in 2011
[11], are mainly economic immigrants and include a sub-
stantial number of unregistered residents; and b) older
women, usually born in Germany or the UK, living in
Mediterranean areas or on the Islands, to which they
moved in middle age or on retirement. These two groups
also differ in terms of screening coverage: while among
older women, the proportion of never screened is higher
in foreigners than in native Spaniards (48% vs. 34%),
among women aged 25–64 years the opposite is true (14%
vs. 27%) [32]. Recent legislation (Royal Law-Decree 16/
2012) has imposed severe restrictions on health-care ac-
cess for undocumented foreign residents and will probably
reduce screening coverage in this subgroup of women,
usually considered a high-risk group for this cancer.
Conclusions
The decline in cervical cancer rates, a disease seen as an
avoidable cause of death, has come to a halt in Spain.
These data indicate that the current prevention pro-
grammes, which are based on opportunistic screening, are
not capable of further reducing the rates, even though the
comparison with other countries, such as Sweden and
Finland, make it clear that there is still room for improve-
ment [2].
Moreover, in the near future, screening will have to
take into account the possible changes in infection dy-
namic derived from HPV vaccination [33], which was in-
cluded in the publicly funded Spanish vaccination
schedule in 2007 [25], and the availability of the HPV test
Cervantes-Amat et al. BMC Cancer  (2015) 15:287 Page 8 of 9[34,35]. The Spanish population-screening programme
network has recently suggested changes in public cervical
cancer screening [36] focused on two main points: a) a
new standard screening protocol, recommending cytology
for sexually-active women under the age of 35 years and
high-risk HPV detection [37] among women over this age
threshold, with new triage and follow-up strategies for
those with positive results; and, b) the incorporation of this
protocol in organised, public, population-based screening
programmes, including adequate surveillance systems to
assess performance. At present, specific strategies should
at least prioritise subgroups of women with low screening
rates, though global public health measures are needed to
reform and reinforce prevention for this neoplasm, in
order to face the challenges posed by cervical cancer in
Spain in the 21st century. In addition, clear actions should
be taken to strengthen cervical cancer surveillance: the
lack of national cancer incidence registries as well as
current problems in the quality of cervical cancer mortality
data are equally important issues that health authorities
should address.
Additional files
Additional file 1: Table S1. Joinpoint regression trend analyses by age
group and geographical region using cervical cancer proportions
obtained from different reference populations.
Additional file 2: Figure S1. Age-standardised cervical cancer mortality
rates in Spain by Autonomous Community (Deaths/100.000 women).
European Standard Population.
Abbreviations
APC: Annual percentage change; CI: Confidence interval; HPV: Human
papilloma virus; U-NOS: Not otherwise specified sites of the uterus;
AAPC: Average annual percentage change.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MCA and BPG were involved in the conception and design of the study,
carried out the data management, performed the statistical analyses and
wrote the manuscript. GLA and RP collected the data and supervised the
statistical analyses. NA and MP contributed to the discussion, interpretation
and review of the manuscript. All authors have read and approved the final
version.
Acknowledgements
This study was supported by a research grant from the Spanish Health Research
Fund [FIS PI11/00871]. Mortality data were furnished by the Spanish National
Statistics Institute under the terms of a specific confidentially protocol.
Author details
1Consortium for Biomedical Research in Epidemiology & Public Health (CIBER
en Epidemiología y Salud Pública - CIBERESP), Avda Monforte de Lemos 5,
28029 Madrid, Spain. 2Cancer and Environmental Epidemiology Unit,
National Centre for Epidemiology, Carlos III Institute of Health, Avda
Monforte de Lemos 5, 28029 Madrid, Spain. 3Puerta de Hierro Biomedical
Research Institute, C/ Joaquín Rodrigo, 2, 28222 Majadahonda, Spain.
Received: 18 November 2014 Accepted: 31 March 2015References
1. Arbyn M, Castellsague X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al.
Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22:2675–86.
2. IARC. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and
Prevalence Worldwide in 2012. IARC. 23-4-2014. http://globocan.iarc.fr.
Accessed 23-Apr-2014
3. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human
papillomavirus and cervical cancer. Lancet. 2007;370:890–907.
4. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European
guidelines for quality assurance in cervical cancer screening. second
edition–summary document. Ann Oncol. 2010;21:448–58.
5. Arbyn M, Raifu A, Autier P, Ferlay J. Burden of cervical cancer in Europe:
estimates for 2004. Ann Oncol. 2007;18:1708–15.
6. INE. Encuesta Nacional de Salud y de Hábitos Sexuales. 2003. http://www.ine.es/.
Accessed 9-May-2014
7. INE. Encuesta Nacional de Salud 2006. 2007. http://www.ine.es/.
Accessed 9-May-2014
8. Pérez-Gómez B, Aragonés N, Pollán M, Suarez B, Lope V, LLácer A, et al.
Accuracy of cancer death certificates in Spain: a summary of available
information. Gac Sanit. 2006;20:42–51.
9. de Souza DL, Curado MP, Bernal MM, Jerez RJ. What is the future burden of
HPV-related cancers in Spain? Clin Transl Oncol. 2014;16:213–9.
10. Loos AH, Bray F, McCarron P, Weiderpass E, Hakama M, Parkin DM. Sheep
and goats: separating cervix and corpus uteri from imprecisely coded
uterine cancer deaths, for studies of geographical and temporal variations
in mortality. Eur J Cancer. 2004;40:2794–803.
11. INE. Cifras de Población y Censos Demográficos. 23-4-2014. http://www.ine.es/.
Accessed 23-Apr-2014
12. NCI. Joinpoint Regression Program Version 2.6. 2014. http://
surveillance.cancer.gov/joinpoint/. Accessed 23-Apr-2014
13. Raifu AO, Arbyn M. Description of cervical cancer mortality in Belgium
using Bayesian age-period-cohort models. Arch Public Health.
2009;67:100–15.
14. Holford TR. Understanding the effects of age, period, and cohort on
incidence and mortality rates. Annu Rev Public Health. 1991;12:425–57.
15. Pastor-Barriuso R, Lopez-Abente G. Changes in period and cohort effects on
haematological cancer mortality in Spain, 1952–2006. BMC Cancer. 2014;14:250.
16. Dean C. Testing for overdispersion in Poisson and binomial regression
models. J Am Stat Assoc. 1992;87:451–7.
17. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint
regression with applications to cancer rates. Stat Med. 2000;19:335–51.
18. Arbyn M, Antoine J, Magi M, Smailyte G, Stengrevics A, Suteu O, et al.
Trends in cervical cancer incidence and mortality in the Baltic countries,
Bulgaria and Romania. Int J Cancer. 2011;128:1899–907.
19. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW,
Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates
for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.
20. Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer
mortality in the member states of the European Union. Eur J Cancer.
2009;45:2640–8.
21. Perez-Gomez B, Martinez C, Navarro C, Franch P, Galceran J, Marcos-Gragera R.
The moderate decrease in invasive cervical cancer incidence rates in
Spain (1980–2004): limited success of opportunistic screening? Ann
Oncol. 2010;21 Suppl 3:iii61–8.
22. de Kok IM, van der Aa MA, van Ballegooijen M, Siesling S, Karim-Kos HE, van
Kemenade FJ, et al. Trends in cervical cancer in the Netherlands until 2007:
has the bottom been reached? Int J Cancer. 2011;128:2174–81.
23. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al.
Annual Report to the Nation on the Status of Cancer, 1975–2009,
featuring the burden and trends in human papillomavirus(HPV)-associated
cancers and HPV vaccination coverage levels. J Natl Cancer Inst.
2013;105:175–201.
24. Trent Cancer Registry. Profile of cervical cancer in England. Incidence,
Mortality and Survival. 2014. http://www.ncin.org.uk/view?rid=1669.
Accessed 5-Jun-2014
25. MSSSi. Revisión del programa de vacunación frente a Virus del Papiloma
Humano en España. 2013. http://aepcc.org/files/
PapilomaVPH_Documento_Ponencia.pdf. Accessed 5-Jun-2014
26. INE. Encuesta Nacional de Salud 2011–2012. 12-5-2014. http://www.ine.es/
jaxi/menu.do?type=pcaxis&path=/t15/p419&file=inebase&L=0. Accessed 9-
May-2014
Cervantes-Amat et al. BMC Cancer  (2015) 15:287 Page 9 of 927. Castro MT. Delayed childbearing in contemporary Spain: trends and
differentials. Eur J Popul. 1992;8:217–46.
28. de Sanjose S, Cortes X, Mendez C, Puig-Tintore L, Torne A, Roura E, et al.
Age at sexual initiation and number of sexual partners in the female
Spanish population Results from the AFRODITA survey. Eur J Obstet
Gynecol Reprod Biol. 2008;140:234–40.
29. Martin-Lopez R, Hernandez-Barrera V, de Andres AL, Carrasco-Garrido P, de
Miguel AG, Jimenez-Garcia R. Trend in cervical cancer screening in Spain
(2003–2009) and predictors of adherence. Eur J Cancer Prev. 2012;21:82–8.
30. Sanz-Barbero B, Regidor E, Galindo S. Impact of geographic origin on
gynecological cancer screening in Spain. Rev Saude Publica. 2011;45:1019–26.
31. Borras JM, Guillen M, Sanchez V, Junca S, Vicente R. Educational level,
voluntary private health insurance and opportunistic cancer screening
among women in Catalonia (Spain). Eur J Cancer Prev. 1999;8:427–34.
32. INE. Encuesta Europea de Salud 2009. 2009. http://www.ine.es. Accessed
12-May-2014
33. Beer H, Hibbitts S, Brophy S, Rahman MA, Waller J, Paranjothy S. Does the
HPV vaccination programme have implications for cervical screening
programmes in the UK? Vaccine. 2014;32:1828–33.
34. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence
regarding human papillomavirus testing in secondary prevention of cervical
cancer. Vaccine. 2012;30 Suppl 5:F88–99.
35. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy
of HPV-based screening for prevention of invasive cervical cancer: follow-up
of four European randomised controlled trials. Lancet. 2014;383:524–32.
36. Red de Programas de Cribado de Cáncer. Recomendaciones de la Red de
Programas de Cribado de Cáncer. 2014. http://
www.programascancerdemama.org/images/archivos/
Cribado_cervix_consenso.pdf. Accessed 5-Jun-2014
37. Dijkstra MG, Snijders PJ, Arbyn M, Rijkaart DC, Berkhof J, Meijer CJ. Cervical
cancer screening: on the way to a shift from cytology to full molecular
screening. Ann Oncol. 2014;25:927–35.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
